复发时延迟治疗淀粉样变直至出现症状：细节决定成败。
Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.
机构信息
Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, MA.
出版信息
Blood Adv. 2019 Jan 22;3(2):216-218. doi: 10.1182/bloodadvances.2018021261.
Abstract
This article has a companion Point by Palladini and Merlini.
摘要
本文有 Palladini 和 Merlini 的相关观点。
相似文献
1
Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.复发时延迟治疗淀粉样变直至出现症状：细节决定成败。
Blood Adv. 2019 Jan 22;3(2):216-218. doi: 10.1182/bloodadvances.2018021261.
2
When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression.在复发时何时应开始治疗 AL 淀粉样变性？早期，以防止器官进展。
Blood Adv. 2019 Jan 22;3(2):212-215. doi: 10.1182/bloodadvances.2018021253.
3
Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation.新的肾脏分期系统在接受大剂量美法仑和干细胞移植治疗的AL淀粉样变性中的验证
Am J Hematol. 2016 Oct;91(10):E458-60. doi: 10.1002/ajh.24464. Epub 2016 Jul 14.
4
Localized Lymph Node Light Chain Amyloidosis.局限性淋巴结轻链淀粉样变。
Intern Med. 2020 Oct 1;59(19):2415-2418. doi: 10.2169/internalmedicine.4651-20. Epub 2020 Jun 30.
5
Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation.高剂量美法仑和干细胞移植治疗AL淀粉样变性中新的肾脏反应标准的预测价值。
Am J Hematol. 2018 May;93(5):E129-E132. doi: 10.1002/ajh.25066. Epub 2018 Feb 24.
6
[Primary amyloidosis].[原发性淀粉样变性]
Med Clin (Barc). 2016 Aug 5;147(3):121-6. doi: 10.1016/j.medcli.2016.02.018. Epub 2016 Apr 13.
7
Stem cell transplantation for immunoglobulin light chain amyloidosis.免疫球蛋白轻链淀粉样变性的干细胞移植
Curr Probl Cancer. 2017 Mar-Apr;41(2):129-137. doi: 10.1016/j.currproblcancer.2017.03.001. Epub 2017 Mar 16.
8
Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.近期系统性轻链淀粉样变的诊断、风险分层和治疗进展。
Acta Haematol. 2019;141(2):93-106. doi: 10.1159/000495455. Epub 2019 Jan 16.
9
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.免疫球蛋白轻链淀粉样变性管理中的新挑战：从基础到临床。
Expert Rev Hematol. 2020 Sep;13(9):1003-1015. doi: 10.1080/17474086.2020.1803060. Epub 2020 Aug 11.
10
Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria.AL淀粉样变性中器官反应的深度与生存率提高相关：新提出的器官反应标准。
Amyloid. 2019;26(sup1):101-102. doi: 10.1080/13506129.2019.1582486.
引用本文的文献
1
Serum free light chain level-based and non-fixed cycle daratumumab treatment strategy for patients with light chain amyloidosis.基于血清游离轻链水平的非固定周期达雷妥尤单抗治疗轻链型淀粉样变性患者的策略
Ann Med. 2025 Dec;57(1):2442075. doi: 10.1080/07853890.2024.2442075. Epub 2024 Dec 19.
2
Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management.肾AL型淀粉样变性：诊断、分期及管理的最新进展
J Clin Med. 2024 Mar 18;13(6):1744. doi: 10.3390/jcm13061744.
3
Diagnosis and Treatment of AL Amyloidosis.诊断与治疗 AL 型淀粉样变。
Drugs. 2023 Feb;83(3):203-216. doi: 10.1007/s40265-022-01830-z. Epub 2023 Jan 18.
4
COVID-19 Exposure Unmasking Systemic Amyloidosis With Hepatic Predominance.新冠病毒暴露揭示以肝脏为主的系统性淀粉样变
Cureus. 2022 Nov 4;14(11):e31092. doi: 10.7759/cureus.31092. eCollection 2022 Nov.
5
Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.轻链稳定：一种改善轻链型淀粉样变性的治疗方法。
Hemato. 2021 Dec;2(4):645-659. doi: 10.3390/hemato2040042. Epub 2021 Oct 5.
6
Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.伴有 CyBorD 加达雷木单抗治疗的患者中无显著轻链升高的肝 AL 淀粉样变性。
Am J Case Rep. 2021 Aug 23;22:e933241. doi: 10.12659/AJCR.933241.
7
Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management.系统性 AL 淀粉样变性：诊断与管理的当前方法
Hemasphere. 2020 Aug 10;4(4):e454. doi: 10.1097/HS9.0000000000000454. eCollection 2020 Aug.
8
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.COVID-19 大流行期间系统性轻链（AL）淀粉样变性患者管理面临的挑战。
Br J Haematol. 2020 Aug;190(3):346-357. doi: 10.1111/bjh.16898. Epub 2020 Jul 4.
9
Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.在复发的淀粉样变多发性骨髓瘤中使用达雷妥尤单抗的安全性、耐受性和应答率：一项 2 期研究的结果。
Blood. 2020 Apr 30;135(18):1541-1547. doi: 10.1182/blood.2019004436.
10
New developments in diagnosis, risk assessment and management in systemic amyloidosis.系统性淀粉样变的诊断、风险评估和治疗的新进展。
Blood Rev. 2020 Mar;40:100636. doi: 10.1016/j.blre.2019.100636. Epub 2019 Nov 2.
本文引用的文献
1
Daratumumab proves safe and highly effective in AL amyloidosis.达雷妥尤单抗在AL淀粉样变性中被证明是安全且高效的。
Br J Haematol. 2019 Apr;185(2):342-344. doi: 10.1111/bjh.15455. Epub 2018 Jun 25.
2
Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.复发/难治性系统性轻链淀粉样变患者的治疗模式和医疗资源利用情况。
Amyloid. 2018 Mar;25(1):1-7. doi: 10.1080/13506129.2017.1411796. Epub 2018 Jan 5.
3
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.二线治疗在既往对非移植治疗敏感的 AL 淀粉样变性中的表现和结果。
Blood. 2018 Feb 1;131(5):525-532. doi: 10.1182/blood-2017-04-780544. Epub 2017 Nov 3.
4
Attitudes about when and how to treat patients with AL amyloidosis: an international survey.何时以及如何治疗 AL 淀粉样变性患者的态度：一项国际调查。
Amyloid. 2017 Dec;24(4):213-216. doi: 10.1080/13506129.2017.1370421. Epub 2017 Aug 31.
5
A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time.AL淀粉样变性患者健康相关生活质量的纵向评估：随时间推移与健康结局的关联。
Br J Haematol. 2017 Nov;179(3):461-470. doi: 10.1111/bjh.14889. Epub 2017 Aug 29.
6
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.AL 淀粉样变性患者自体干细胞移植后二线治疗时机的划定。
Blood. 2017 Sep 28;130(13):1578-1584. doi: 10.1182/blood-2017-05-783415. Epub 2017 Aug 14.
7
Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.大剂量美法仑和干细胞移植后AL淀粉样变性的血液学复发
Blood. 2017 Sep 14;130(11):1383-1386. doi: 10.1182/blood-2017-06-788729. Epub 2017 Jul 11.
8
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.达雷妥尤单抗可使经过大量预处理的 AL 淀粉样变性患者获得快速且深度的血液学缓解。
Blood. 2017 Aug 17;130(7):900-902. doi: 10.1182/blood-2017-01-763599. Epub 2017 Jun 14.
9
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.口服蛋白酶体抑制剂伊沙佐米用于复发或难治性AL淀粉样变性的1/2期研究。
Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.
10
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.2000年至2014年间新诊断的AL淀粉样变性患者的预后改善：突破早期死亡的瓶颈
Blood. 2017 Apr 13;129(15):2111-2119. doi: 10.1182/blood-2016-11-751628. Epub 2017 Jan 26.
Zotero 插件